BioCryst Pharmaceuticals’ (BCRX) In-Line Rating Reaffirmed at Evercore ISI

Evercore ISI reaffirmed their in-line rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research note issued to investors on Wednesday, Marketbeat Ratings reports. Evercore ISI currently has a $8.00 price objective on the biotechnology company’s stock.

Several other research firms have also recently commented on BCRX. Needham & Company LLC restated a “buy” rating and set a $17.00 price target on shares of BioCryst Pharmaceuticals in a report on Monday, August 4th. Wedbush raised their price target on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock an “outperform” rating in a report on Monday, June 30th. Royal Bank Of Canada restated an “outperform” rating and set a $13.00 price target on shares of BioCryst Pharmaceuticals in a report on Monday, June 30th. Wall Street Zen upgraded shares of BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 26th. Finally, Bank of America raised their price target on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, July 1st. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $16.30.

BioCryst Pharmaceuticals Price Performance

BioCryst Pharmaceuticals stock opened at $7.15 on Wednesday. The firm’s 50 day simple moving average is $8.11 and its 200-day simple moving average is $8.70. The company has a market cap of $1.50 billion, a P/E ratio of -39.72, a price-to-earnings-growth ratio of 1.47 and a beta of 1.05. BioCryst Pharmaceuticals has a fifty-two week low of $6.01 and a fifty-two week high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.12. The firm had revenue of $163.35 million during the quarter, compared to analysts’ expectations of $149.59 million. The business’s revenue was up 49.5% on a year-over-year basis. During the same period last year, the business earned ($0.06) earnings per share. On average, analysts expect that BioCryst Pharmaceuticals will post -0.36 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Theresa Heggie sold 70,000 shares of the stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total value of $595,700.00. Following the transaction, the director owned 65,352 shares in the company, valued at approximately $556,145.52. This represents a 51.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. Osaic Holdings Inc. increased its holdings in BioCryst Pharmaceuticals by 10.1% in the second quarter. Osaic Holdings Inc. now owns 48,611 shares of the biotechnology company’s stock worth $436,000 after buying an additional 4,466 shares during the last quarter. Headlands Technologies LLC increased its holdings in BioCryst Pharmaceuticals by 1,208.9% in the second quarter. Headlands Technologies LLC now owns 55,221 shares of the biotechnology company’s stock worth $495,000 after buying an additional 51,002 shares during the last quarter. CANADA LIFE ASSURANCE Co increased its holdings in BioCryst Pharmaceuticals by 20.5% in the second quarter. CANADA LIFE ASSURANCE Co now owns 60,906 shares of the biotechnology company’s stock worth $546,000 after buying an additional 10,361 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in BioCryst Pharmaceuticals by 213.7% in the second quarter. Tower Research Capital LLC TRC now owns 21,758 shares of the biotechnology company’s stock worth $195,000 after buying an additional 14,822 shares during the last quarter. Finally, Exome Asset Management LLC grew its holdings in BioCryst Pharmaceuticals by 185.3% during the second quarter. Exome Asset Management LLC now owns 172,883 shares of the biotechnology company’s stock valued at $1,549,000 after purchasing an additional 112,283 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.